Arvinas (ARVN) News Today $18.48 +0.65 (+3.65%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Arvinas, Inc. (NASDAQ:ARVN) Stake Lowered by State Street CorpState Street Corp trimmed its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 3.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,643,727 shares of the company's stock after selling 55,961 shares during theDecember 21 at 3:40 AM | marketbeat.comArvinas (NASDAQ:ARVN) Stock Price Down 6.2% - Here's What HappenedArvinas (NASDAQ:ARVN) Shares Down 6.2% - Here's What HappenedDecember 19 at 4:14 PM | marketbeat.comArvinas (NASDAQ:ARVN) Sets New 12-Month Low - What's Next?Arvinas (NASDAQ:ARVN) Hits New 1-Year Low - Should You Sell?December 18 at 5:37 PM | marketbeat.comContrasting Unicycive Therapeutics (NASDAQ:UNCY) & Arvinas (NASDAQ:ARVN)December 17, 2024 | americanbankingnews.comBuy Rating for Arvinas Holding Company Driven by Vepdeg’s Promising Potential and Market OpportunityDecember 16, 2024 | markets.businessinsider.comArvinas, Inc. (NASDAQ:ARVN) Short Interest Up 5.6% in NovemberArvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 9,020,000 shares, a growth of 5.6% from the November 15th total of 8,540,000 shares. Based on an average daily trading volume, of 577,200 shares, the days-to-cover ratio is presently 15.6 days.December 16, 2024 | marketbeat.comBarclays Keeps Their Buy Rating on Arvinas Holding Company (ARVN)December 14, 2024 | markets.businessinsider.comGuggenheim Reiterates "Buy" Rating for Arvinas (NASDAQ:ARVN)December 14, 2024 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Holdings Lowered by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 55.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,349 shares of the company's stock after selDecember 12, 2024 | marketbeat.comPromising Potential and Strong Efficacy of Arvinas Holding’s Vepdeg+Abema Combination Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comDemystifying Arvinas: Insights From 5 Analyst ReviewsDecember 11, 2024 | benzinga.comArvinas Holding Company (ARVN) Receives a Buy from Evercore ISIDecember 11, 2024 | markets.businessinsider.comArvinas (NASDAQ:ARVN) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $87.00 target price on shares of Arvinas in a research report on Wednesday.December 11, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Earns Buy Rating from Analysts at BTIG ResearchDecember 11, 2024 | americanbankingnews.comArvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination TherapyDecember 10, 2024 | markets.businessinsider.comArvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer SymposiumDecember 10, 2024 | globenewswire.comArvinas (NASDAQ:ARVN) Coverage Initiated by Analysts at BTIG ResearchBTIG Research initiated coverage on Arvinas in a report on Tuesday. They set a "buy" rating and a $69.00 target price for the company.December 10, 2024 | marketbeat.comVerition Fund Management LLC Cuts Stock Position in Arvinas, Inc. (NASDAQ:ARVN)Verition Fund Management LLC decreased its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 57.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,631 shares of the compDecember 9, 2024 | marketbeat.comFmr LLC Grows Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)Fmr LLC lifted its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 7.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,883,604 shares of the company's stock after purchasing an additional 204,317 shDecember 7, 2024 | marketbeat.comRTW Investments LP Trims Stock Position in Arvinas, Inc. (NASDAQ:ARVN)RTW Investments LP lowered its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 6.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 2,782,329 shares of the company's stock after selling 185,568 shares during the period. RTW Investments LP oDecember 5, 2024 | marketbeat.comWhy Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comParkman Healthcare Partners LLC Sells 28,978 Shares of Arvinas, Inc. (NASDAQ:ARVN)Parkman Healthcare Partners LLC cut its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 23.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 96,183 shares of the compaDecember 4, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNDecember 3, 2024 | prnewswire.comBaker BROS. Advisors LP Takes Position in Arvinas, Inc. (NASDAQ:ARVN)Baker BROS. Advisors LP acquired a new position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 405,576 shares of the company's stock, valuDecember 2, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from BrokeragesArvinas, Inc. (NASDAQ:ARVN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buDecember 2, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Shares Bought by Wasatch Advisors LPWasatch Advisors LP lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 58.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 435,943 shares of the company's stock after buying an additional 160,510 shareDecember 1, 2024 | marketbeat.comBraidwell LP Boosts Stock Position in Arvinas, Inc. (NASDAQ:ARVN)Braidwell LP boosted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 148.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,284,472 shares of the company's stock after acquiring an adNovember 29, 2024 | marketbeat.comArvinas to Present at Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.comPositive Outlook for Arvinas Due to Promising Safety Data and Upcoming DevelopmentsNovember 26, 2024 | markets.businessinsider.comArvinas Holding Co.: Promising Advances in Breast Cancer Treatment Drive Buy RatingNovember 26, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNNovember 25, 2024 | prnewswire.comArvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer SymposiumNovember 25, 2024 | globenewswire.comAlgert Global LLC Purchases 123,613 Shares of Arvinas, Inc. (NASDAQ:ARVN)Algert Global LLC grew its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 278.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 168,061 shares of the company's stock after acquiring an additional 123,613 shares during the quarter. Algert GNovember 25, 2024 | marketbeat.comLeerink Partnrs Issues Negative Outlook for Arvinas EarningsArvinas, Inc. (NASDAQ:ARVN - Free Report) - Leerink Partnrs cut their FY2025 earnings per share estimates for Arvinas in a report issued on Tuesday, November 19th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($2.98) per share for the year, down from their previousNovember 22, 2024 | marketbeat.comArvinas Holding’s VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price TargetNovember 22, 2024 | markets.businessinsider.comArvinas price target lowered to $88 from $90 at BMO CapitalNovember 20, 2024 | markets.businessinsider.comStephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight RecommendationNovember 19, 2024 | msn.comArvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | insidermonkey.comArvinas initiated with an Overweight at StephensNovember 18, 2024 | markets.businessinsider.comStephens Begins Coverage on Arvinas (NASDAQ:ARVN)Stephens assumed coverage on shares of Arvinas in a research report on Monday. They issued an "overweight" rating and a $55.00 price target on the stock.November 18, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Short Interest UpdateArvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 8,800,000 shares, a decline of 5.6% from the October 15th total of 9,320,000 shares. Based on an average daily volume of 545,500 shares, the days-to-cover ratio is currently 16.1 days.November 18, 2024 | marketbeat.comClearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular EdemaNovember 7, 2024 | globenewswire.comArvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Moderate Buy" from AnalystsArvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buyNovember 7, 2024 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Arvinas Holding Company (ARVN)November 4, 2024 | markets.businessinsider.comArvinas to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comFY2024 EPS Estimates for Arvinas Cut by Leerink PartnrsArvinas, Inc. (NASDAQ:ARVN - Free Report) - Investment analysts at Leerink Partnrs cut their FY2024 EPS estimates for shares of Arvinas in a report issued on Thursday, October 31st. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($2.70) per share for theNovember 4, 2024 | marketbeat.comArvinas price target lowered to $40 from $50 at OppenheimerNovember 2, 2024 | markets.businessinsider.comAndrew Fein’s Buy Rating for Arvinas: Vepdeg’s Promising Clinical Potential and Market AppealNovember 1, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Arvinas Holding Company (ARVN)November 1, 2024 | markets.businessinsider.comArvinas (NASDAQ:ARVN) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $87.00 price objective on shares of Arvinas in a research note on Thursday.October 31, 2024 | marketbeat.com Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years. I call it my AI Retirement Playbook. I recommend you check it out now. ARVN Media Mentions By Week ARVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARVN News Sentiment▼0.360.61▲Average Medical News Sentiment ARVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARVN Articles This Week▼75▲ARVN Articles Average Week Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BBIO News Today CRNX News Today KRYS News Today ACLX News Today ADMA News Today RARE News Today APLS News Today BHVN News Today IMVT News Today RNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARVN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts